MNG
NVS icon

Manning & Napier Group’s Novartis NVS Stock Holding History

Manning & Napier Group’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$101M Sell
1,042,426
-14,742
-1% -$1.51M 1.15% 28
2023
Q4 		$107M Sell
1,057,168
-12,025
-1% -$1.16M 1.27% 24
2023
Q3 		$109M Sell
1,069,193
-16,638
-2% -$1.69M 1.35% 19
2023
Q2 		$110M Sell
1,085,831
-673,799
-38% -$67.4M 1.25% 21
2023
Q1 		$162M Buy
1,759,630
+1,531
+0.1% +$134K 1.89% 10
2022
Q4 		$159M Sell
1,758,099
-32,591
-2% -$2.75M 1.96% 10
2022
Q3 		$136M Sell
1,790,690
-12,243
-0.7% -$1.01M 1.78% 12
2022
Q2 		$152M Sell
1,802,933
-33,047
-2% -$2.9M 1.76% 11
2022
Q1 		$161M Sell
1,835,980
-92,246
-5% -$7.99M 1.53% 12
2021
Q4 		$169M Buy
1,928,226
+18,232
+1% +$1.51M 1.41% 17
2021
Q3 		$156M Buy
1,909,994
+25,665
+1% +$2.31M 1.34% 19
2021
Q2 		$172M Buy
1,884,329
+153,982
+9% +$13.7M 1.41% 15
2021
Q1 		$148M Sell
1,730,347
-407,958
-19% -$36.6M 1.26% 18
2020
Q4 		$202M Sell
2,138,305
-52,060
-2% -$4.55M 1.88% 9
2020
Q3 		$190M Buy
2,190,365
+62,239
+3% +$5.39M 1.93% 8
2020
Q2 		$186M Sell
2,128,126
-90,509
-4% -$7.81M 1.99% 8
2020
Q1 		$183M Buy
2,218,635
+58,901
+3% +$5.26M 2.16% 9
2019
Q4 		$205M Sell
2,159,734
-253,817
-11% -$22.8M 2.21% 8
2019
Q3 		$210M Sell
2,413,551
-85,376
-3% -$7.67M 2.35% 5
2019
Q2 		$228M Sell
2,498,927
-1,143,094
-31% -$96.7M 2.48% 6
2019
Q1 		$314M Sell
3,642,021
-169,350
-4% -$13.6M 3.43% 1
2018
Q4 		$293M Sell
3,811,371
-79,009
-2% -$6.15M 3.57% 1
2018
Q3 		$300M Sell
3,890,380
-218,771
-5% -$16.2M 2.95% 3
2018
Q2 		$278M Sell
4,109,151
-82,169
-2% -$5.67M 2.74% 6
2018
Q1 		$304M Sell
4,191,320
-184,423
-4% -$14M 2.98% 4
2017
Q4 		$329M Buy
+4,375,743
New +$330M 2.96% 4

Other funds holding NVS

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Manning & Napier Group's NVS Position: Q1 2024 in Review

Manning & Napier Group reduced its Novartis (NVS) stake by 1.4% in Q1 2024, selling an estimated $1.51M and leaving 1,042,426 shares worth $101M. The position accounts for 1.15% of the portfolio, ranked #28.

Manning & Napier Group first reported a position in NVS in Q4 2017 and has held it in 26 quarters since. The position peaked at $329M in Q4 2017. 1,254 funds tracked by Wall St. Rank hold NVS as of Q1 2024.

  • Manning & Napier Group held 1,042,426 shares of Novartis worth $101M as of Q1 2024.
  • Manning & Napier Group sold 14,742 Novartis shares in Q1 2024, an estimated $1.51M.
  • Novartis made up 1.15% of Manning & Napier Group's portfolio in Q1 2024, its #28 holding.
  • Manning & Napier Group first reported a position in Novartis in Q4 2017 and has held it in 26 quarters since.
  • Manning & Napier Group's Novartis position peaked at $329M in Q4 2017.
  • 1,254 funds tracked by Wall St. Rank held Novartis as of Q1 2024.

Based on Manning & Napier Group's 13F filing for Q1 2024, filed 15 Apr 2024.